Authors
Chuqiao Zhang, Minyang Zhang, Qingqing Jiao, Yujie Ding
Published in
Experimental dermatology. Volume 35. Issue 11.
Abstract
Chronic spontaneous urticaria (CSU) is a common, distressing skin disease driven by dysregulated immune responses. OX40 is a key costimulatory molecule implicated in Type 2 inflammation, yet the role of memory T cell subsets and the OX40/OX40L co-stimulatory axis in driving CSU pathogenesis remains poorly defined. To characterize the peripheral frequencies of memory T cell subsets and OX40 expression patterns in patients with CSU, and to explore their associations with disease activity and autoimmune features, this study comprised two parts. Part 1 was a retrospective cohort analysis including 110 patients with CSU, examining the relationship between memory T-cell subset frequencies and clinical parameters. Part 2 was a prospective nested case-control study including 30 age- and sex-matched CSU patients (overlapping with Part 1) and 30 healthy controls (HCs), utilizing flow cytometry to assess OX40 expression on T-cell subsets. Memory T cell subsets (naïve, central memory [TCM], effector memory [TEM]) and the percentages of OX40-positive cells were analysed by flow cytometry. Key clinical parameters, including disease activity (7-day Urticaria Activity Score, UAS7), health-related quality of life (Dermatology Life Quality Index, DLQI), and thyroid autoantibody levels, were evaluated. CSU patients showed an imbalanced memory T cell profile, with increased frequencies of CD4+ TEM and reduced frequencies of CD4+ TCM. The percentage of OX40-positive cells was significantly elevated on CD4+ TCM in CSU compared with HCs (p = 0.005) and positively correlated with disease severity (UAS7: rs = 0.574, p = 0.001), impaired health-related quality of life (DLQI: rs = 0.889, p < 0.001), and serum levels of thyroid peroxidase antibodies (TPOAb: rs = 0.418, p = 0.03). Our findings reveal dysregulated OX40 expression on memory T cells in CSU, linking it to disease severity and autoimmune features, thus identifying OX40 as a promising novel therapeutic target for patients with refractory CSU, especially those with autoimmune comorbidities.
PMID:
43031262
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0